Mutation and expression analysis of PTEN in non-small cell lung cancer from non-smokers

2008 ◽  
Author(s):  
Yin-wah Lau
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Expression Analysis ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Expression Analysis of OIP5-AS1 in Non-Small Cell Lung Cancer

2018 ◽  
Vol 31 (4) ◽  
Author(s):  
Farbod Esfandi ◽  
Kholghi Oskooei Vahid ◽  
Taheri Fatemeh ◽  
Arda Kiani ◽  
Mohammad Taheri ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Expression Analysis ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Gene expression analysis of microtubule affinity-regulating kinase 2 in non-small cell lung cancer

Genomics Data ◽  
2015 ◽  
Vol 6 ◽  
pp. 145-148 ◽  
Author(s):  
Erin A. Marshall ◽  
Kevin W. Ng ◽  
Christine Anderson ◽  
Roland Hubaux ◽  
Kelsie L. Thu ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Expression Analysis ◽  
Cell Lung Cancer ◽  
Gene Expression Analysis ◽  
Small Cell ◽  
Small Cell Lung

Gene expression analysis in non small cell lung cancer (NSCLC) using microarray technology

2003 ◽  
Vol 64 (10) ◽  
pp. S116
Author(s):  
Paolo Fardin ◽  
Jurg Bahler ◽  
Paolo Capanni ◽  
Erika Inglese ◽  
Annamaria Ricciardi ◽  
...  
Keyword(s):  
Gene Expression ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Expression Analysis ◽  
Cell Lung Cancer ◽  
Gene Expression Analysis ◽  
Small Cell ◽  
Microarray Technology ◽  
Small Cell Lung

scholarly journals 114P: Expression analysis of tumorspheres from non-small cell lung cancer show significant differences in CSC-markers and signaling pathways

2016 ◽  
Vol 11 (4) ◽  
pp. S105
Author(s):  
A. Herreros Pomares ◽  
E. Munera Maravilla ◽  
B. Lafuente ◽  
S. Calabuig-Fariñas ◽  
A. Blasco Cordellat ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Signaling Pathways ◽  
Expression Analysis ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer

2013 ◽  
Vol 31 (19) ◽  
pp. 2404-2412 ◽  
Author(s):  
Gerold Bepler ◽  
Charles Williams ◽  
Michael J. Schell ◽  
Wei Chen ◽  
Zhong Zheng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Expression Analysis ◽  
Cell Lung Cancer ◽  
Progression Free Survival ◽  
Median Number ◽  
Small Cell ◽  
Phase Iii ◽  
Small Cell Lung ◽  
Protein Levels

Purpose We assessed whether chemotherapy selection based on in situ ERCC1 and RRM1 protein levels would improve survival in patients with advanced non–small-cell lung cancer (NSCLC). Patients and Methods Eligible patients were randomly assigned 2:1 to the trial's experimental arm, which consisted of gemcitabine/carboplatin if RRM1 and ERCC1 were low, docetaxel/carboplatin if RRM1 was high and ERCC1 was low, gemcitabine/docetaxel if RRM1 was low and ERCC1 was high, and docetaxel/vinorelbine if both were high. In the control arm, patients received gemcitabine/carboplatin. The trial was powered for a 32% improvement in 6-month progression-free survival (PFS). Results Of 331 patients registered, 275 were eligible. The median number of cycles given was four in both arms. A tumor rebiopsy specifically for expression analysis was required in 17% of patients. The median time from informed consent to expression analysis was 11 days. We found no statistically significant differences between the experimental arm and the control arm in PFS (6.1 months v 6.9 months) or overall survival (11.0 months v 11.3 months). A subset analysis revealed that patients with low levels for both proteins who received the same treatment in both treatment arms had a statistically better PFS (P = .02) in the control arm (8.1 months) compared with the experimental arm (5.0 months). Conclusion This demonstrates that protein expression analysis for therapeutic decision making is feasible in newly diagnosed patients with advanced-stage NSCLC. A tumor rebiopsy is safe, required in 17%, and acceptable to 89% (47 of 53) of patients.

Sign in / Sign up

Export Citation Format

Share Document